Study #2023-1048
A phase 2, open-label, multicenter study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in adult participants with relapsed or refractory multiple myeloma (QUINTESSENTIAL)
MD Anderson Study Status
Enrolling
Treatment Agent
Arlocabtagene Autoleucel (BMS-986393)
Description
The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Multiple Myeloma
Study phase:
Phase II
Physician name:
Krina Patel
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-701-9908
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.